KBC Group NV lowered its position in shares of Merus N.V. (NASDAQ:MRUS - Free Report) by 94.9% in the 1st quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 2,901 shares of the biotechnology company's stock after selling 54,333 shares during the quarter. KBC Group NV's holdings in Merus were worth $122,000 at the end of the most recent quarter.
Other institutional investors have also made changes to their positions in the company. GAMMA Investing LLC lifted its stake in shares of Merus by 2,153.6% in the 1st quarter. GAMMA Investing LLC now owns 631 shares of the biotechnology company's stock valued at $27,000 after purchasing an additional 603 shares during the last quarter. State of Wyoming acquired a new stake in shares of Merus during the 4th quarter worth approximately $48,000. Wells Fargo & Company MN lifted its stake in Merus by 27.3% during the fourth quarter. Wells Fargo & Company MN now owns 1,400 shares of the biotechnology company's stock worth $59,000 after purchasing an additional 300 shares during the period. GF Fund Management CO. LTD. acquired a new position in shares of Merus in the 4th quarter worth approximately $60,000. Finally, Lazard Asset Management LLC acquired a new position in shares of Merus in the 4th quarter worth approximately $84,000. 96.14% of the stock is owned by hedge funds and other institutional investors.
Merus Stock Performance
Shares of MRUS stock traded down $0.61 during trading on Friday, hitting $54.50. The company had a trading volume of 315,839 shares, compared to its average volume of 738,704. The firm has a market capitalization of $3.77 billion, a P/E ratio of -13.36 and a beta of 1.00. The stock's 50-day moving average price is $50.55 and its 200 day moving average price is $45.53. Merus N.V. has a one year low of $33.19 and a one year high of $62.98.
Merus (NASDAQ:MRUS - Get Free Report) last announced its quarterly earnings data on Wednesday, May 14th. The biotechnology company reported ($1.40) EPS for the quarter, missing the consensus estimate of ($1.17) by ($0.23). The firm had revenue of $26.49 million for the quarter, compared to analyst estimates of $7.82 million. Merus had a negative net margin of 506.73% and a negative return on equity of 35.99%. On average, research analysts anticipate that Merus N.V. will post -3.85 earnings per share for the current fiscal year.
Insider Activity
In other Merus news, COO Peter B. Silverman sold 34,000 shares of the stock in a transaction that occurred on Friday, June 20th. The shares were sold at an average price of $52.76, for a total transaction of $1,793,840.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Insiders have sold 57,500 shares of company stock worth $3,086,340 in the last three months. 4.57% of the stock is currently owned by corporate insiders.
Analyst Upgrades and Downgrades
MRUS has been the topic of a number of research analyst reports. William Blair restated an "outperform" rating on shares of Merus in a research report on Monday, April 28th. BMO Capital Markets set a $110.00 price target on Merus and gave the stock an "outperform" rating in a research report on Friday, May 23rd. Wells Fargo & Company dropped their price objective on Merus from $91.00 to $89.00 and set an "overweight" rating on the stock in a research note on Thursday, May 8th. Guggenheim reiterated a "buy" rating and issued a $109.00 price target on shares of Merus in a research note on Friday, March 28th. Finally, Needham & Company LLC reaffirmed a "buy" rating and issued a $75.00 target price on shares of Merus in a research report on Monday, May 19th. Twelve research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the stock. According to data from MarketBeat.com, Merus presently has a consensus rating of "Buy" and a consensus target price of $84.64.
View Our Latest Stock Report on MRUS
Merus Profile
(
Free Report)
Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer and castration-resistant prostate cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1.
See Also
Before you consider Merus, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Merus wasn't on the list.
While Merus currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
